Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Androgen receptor regulated long noncoding RNA 1 (ARLNC1)
- Target
- ARLNC1
- Molecular classification
- Long noncoding RNA, Other (non-protein coding gene)
01
Overview
Androgen receptor regulated long noncoding RNA 1 (ARLNC1) is a prostate-specific long noncoding RNA directly regulated by androgen receptor (AR) signaling. ARLNC1 forms a positive feedback loop by stabilizing AR transcript via RNA-RNA interaction, which potentiates AR signaling and enhances prostate cancer cell proliferation and survival[1][2][4][5][6][7][8]. Knockdown of ARLNC1—using RNA interference or antisense oligonucleotides—suppresses AR levels, global AR signaling, and tumor growth both in vitro and in vivo[1][6]. ARLNC1 is under investigation as a therapeutic target and as a biomarker for AR-driven prostate cancer[1][6]. No approved drugs currently target ARLNC1 directly, though RNA-targeted approaches are in development.
- Other names
- PRCAT47LINC02170prostate cancer-associated 47AR-regulated long noncoding RNA 1long intergenic non-protein coding RNA 2170
02
Mechanism of action
Antisense oligonucleotides (ASOs): inhibit ARLNC1, leading to reduced AR transcript stability and signaling, suppressed prostate cancer growth
03
Biological functions
Regulation of androgen receptor signalingRegulation of cell proliferationRegulation of apoptosisRegulation of DNA damage response
04
Disease associations
Cancer (especially prostate cancer and castration-resistant prostate cancer)
05
Safety considerations
Possible tissue-specific effects, as ARLNC1 is expressed almost exclusively in prostate tissueNeed for further characterization of off-target effects when using nucleotide-based therapies
06
Interacting drugs
Antisense oligonucleotides (ASOs)
07
Biomarkers
ARLNC1 expression in prostate tissue as a mechanistic/predictive biomarker (potential utility for advanced prostate cancer and as a marker for resistance to therapies targeting AR signaling)
Beyond the preview
Go deeper on Androgen receptor regulated long noncoding RNA 1 (ARLNC1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Androgen receptor regulated long noncoding RNA 1 (ARLNC1).